Cause of kids' sickness outbreak in Llangollen confirmed by public health chiefs
The cause of an outbreak that forced a concert to be cancelled at the Llangollen International Eisteddfod last night (Wednesday), has been confirmed by health chiefs.
A number of children were taken to hospital with "flu-like symptoms" and an "extraordinary medical incident was declared by the Welsh Ambulance Service.
Sir Karl Jenkins was scheduled to take centre stage at the Pavilion and conduct his powerful masterpiece, One World, live. It was billed as a concert that "brings together voices from around the globe to celebrate peace, harmony, and the universal language of music." It is the first time in the Eisteddfod's history it has had to cancel an event in this way.
Sign up for the North Wales Live newsletter sent twice daily to your inbox
In a further update today (Thursday) Dr Giri Shankar, Director of Health Protection for Public Health Wales, said: 'The visitors to the Llangollen International Eisteddfod who were assessed in hospital last night will be discharged this morning.
"Tests carried out on these children have indicated the presence of common respiratory viruses, including flu. They are being treated appropriately and are recovering. The risk to the public remains low'.
Earlier Chris Williams, Consultant in Health Protection for PHW, said: 'We are aware that a small group of children who were visiting the Eisteddfod at Llangollen were taken to hospital this evening (Wednesday). Currently, the children are being medically assessed for mild respiratory symptoms, but they are not seriously unwell.'
The Llangollen International Eisteddfod issued two statements last night as the emergency unfolded. The first said: "Due to an extraordinary medical incident - tonight's event has been cancelled.
"We want to thank our own medical teams who are managing the extraordinary medical incident. We are working with the Ambulance services and medical teams managing the incident giving them the support necessary.
"The Llangollen International Eisteddfod intends to run as normal from 9am tomorrow, but this will be based on the expert medical advice we receive. We apologise for any inconvenience caused."
Another statement was released by the festival later, which gave more details and also confirming the site was clear to reopen by 9am today.
It said: "Further to the previous statement, we can confirm that following the declaration of an extraordinary incident by the Welsh Ambulance Service, following Public Health Wales advice - the incident related to a flu-like outbreak and related to multiple people with similar symptoms. The extraordinary incident was called by the Welsh Ambulance Service due to the number of people who presented ill at one time.
"We are pleased to report our site has been cleared to reopen tomorrow at 9am, as we continue to welcome the world to Wales. We'd like to thank our staff, medical staff and our volunteers for their swift response this evening."
Join the North Wales Live WhatsApp community group where you can get the latest stories delivered straight to your phone
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
5 hours ago
- Reuters
Rocket Pharma's shares soar after US FDA lets gene therapy trial resume
Aug 20 (Reuters) - The U.S. health regulator has allowed a study of Rocket Pharmaceuticals' (RCKT.O), opens new tab gene therapy to resume, less than three months after halting it following a patient's death. The drugmaker's shares soared over 30% in morning trading on Wednesday. Rocket's mid-stage trial, testing its experimental therapy, RP-A501, for a genetic disorder called Danon disease, was halted in May by the Food and Drug Administration after a patient died from a rare complication. The company said on Wednesday that the FDA has lifted its clinical hold on the trial, to be resumed with a revised pre-treatment regime and a lower dose of the gene therapy. Rocket said it will discontinue prophylactic use of drugs that inhibit the C3 protein, which is part of the immune system, as part of the pre-treatment regime. The patient who died in the May trial was one of two who were administered the C3 inhibitors. The patient had suffered from capillary leak syndrome, which can cause organ failure. In the new trial, three patients, at least four weeks apart, are expected to receive a lower dose of its therapy. Rocket said the adjusted dose was proposed based on data from an early-stage study, which showed a better safety profile. Danon disease, which affects males more severely than females, causes heart muscle damage and progressive muscle weakness. Fewer than 1,000 people in the United States are currently known to have the condition, according to National Institutes of Health.
Reuters
7 hours ago
- Reuters
Healthcare firms see growing activist investor involvement in the past year
Aug 20 (Reuters) - Activist investors have targeted major healthcare companies over the past year to push them to improve their performance, with some campaigns only coming to light after announcements of board changes. Below are some notable healthcare companies that came under activist pressure in the last 12 months. MEDTRONIC (MDT.N), opens new tab In August 2025, the medical device maker appointed two new independent directors to its board and created independent committees focused on improving its performance, after Elliott Investment Management took a large stake, making it one of the company's biggest shareholders. AVANTOR (AVTR.N), opens new tab Engine Capital targeted the life sciences firm in August 2025, urging it to bring in new board directors, cut costs and even consider a sale. CHARLES RIVER LABORATORIES (CRL.N), opens new tab The contract research firm settled with Elliott Investment Management in May 2025 by agreeing to add four new board directors and launch a strategic review of the business. Activist hedge fund Parvus Asset Management is building a stake in the company, as investors have grown concerned that the Danish drugmaker has lost its first-mover advantage in the lucrative weight-loss drug market, the Financial Times reported in June 2025. Reuters has not independently verified the report. GERRESHEIMER ( opens new tab London-based investment fund Asset Value Investors in June 2025 pressed the German medical packaging maker to find ways to restore its market value. AVI, with a 3.5% stake in Gerresheimer, said the company needs a new financial leadership to regain its credibility. ILLUMINA (ILMN.O), opens new tab In March 2025, the gene-sequencing maker said activist investor Keith Meister would join its board. HENRY SCHEIN (HSIC.O), opens new tab In January, private equity firm KKR (KKR.N), opens new tab built a large stake in the medical and dental supplies distributor and reached a deal to add members to the company's board. Henry Schein was also under pressure from other investors, including Ananym Capital Management. PFIZER (PFE.N), opens new tab Activist hedge fund Starboard Value in October 2024 called for management accountability for the company's underperformance. This month, Starboard increased, opens new tab its holding in the drugmaker to 8.5 million shares, which represented about 0.15% of the outstanding shares as of June end. KENVUE (KVUE.N), opens new tab In October 2024, Starboard Value took a significant stake in the Band-Aid maker, criticizing the weak performance of its skin health segment, which houses Neutrogena, Aveeno and other brands. After a proxy battle, the companies reached a deal in early 2025 that gave Starboard CEO Jeffrey Smith and two independent directors board seats. CVS HEALTH (CVS.N), opens new tab In November, CVS Health added Glenview Capital's top boss and three others to its board as part of a deal with the hedge fund. The company had been under pressure from investors, including Glenview, to improve operations after missing financial targets several times due to rising medical costs in its health insurance business. Glenview reduced its stake in the company after CVS posted strong results in May.
Medical News Today
18 hours ago
- Medical News Today
Zilbrysq side effects and how to manage them
As with other drugs, Zilbrysq (zilucoplan) can cause side effects, such as injection site reaction and upper respiratory tract infection. If these side effects become difficult to tolerate, talk with your doctor or (zilucoplan) is a brand-name subcutaneous injection prescribed for generalized myasthenia gravis in adults. If you have problems with side effects from Zilbrysq, talk with your doctor or pharmacist. They can discuss ways to manage side effects or other available treatment options. Do not stop taking Zilbrysq without consulting your doctor has a boxed warning. A boxed warning is the most serious warning from the Food and Drug Administration (FDA). For details, see the 'Boxed warnings for Zilbrysq' section.»Learn more about Zilbrysq, including details about its common side effects of ZilbrysqZilbrysq can cause certain side effects, some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. However, if the side effects persist, bother you, or become severe, be sure to talk with your doctor or pharmacist. These are just a few of the more common side effects reported by people who took Zilbrysq in clinical trials:diarrheaupper respiratory tract infectioninjection site reactionMild side effects of ZilbrysqMild side effects can occur with Zilbrysq use. This list may not include all possible mild side effects of the drug. To find out more, you can refer to Zilbrysq's prescribing side effects that people receiving Zilbrysq have reported include:nausea and vomitingdiarrheaupper respiratory tract infectioninjection site reactionurinary tract infection (UTI)These side effects may be temporary, lasting a few days to weeks. However, if the side effects continue, worsen, or become too difficult to tolerate, be sure to talk with your doctor or After the Food and Drug Administration (FDA) approves a drug, it tracks and reviews side effects of the medication. Sharing your experience helps make medications safer for everyone by giving doctors and researchers more information about how the drug works in real life. If you develop a side effect while taking Zilbrysq and want to tell the FDA about it, visit MedWatch or call side effects of ZilbrysqZilbrysq may cause serious side effects. The following list may not include all possible serious side effects of the drug. For more information, you can refer to Zilbrysq's prescribing you develop serious side effects while taking Zilbrysq, call your doctor right away. If the side effects seem life threatening or you think you're having a medical emergency, immediately call 911 or your local emergency side effects that people receiving Zilbrysq have reported include:increased risk of bacterial infections, such as gonorrheapancreatitis (inflammation of the pancreas) or other pancreatic conditionsserious meningococcal infection (See 'Boxed warnings')Allergic reactionFor some people, Zilbrysq can cause an allergic this side effect wasn't reported in the drug's general, symptoms of allergic reaction can be mild or to manageFor mild allergic reaction symptoms, such as a mild rash, call your doctor right away. They may recommend treatments to help manage your symptoms. They'll also let you know whether you should keep taking the severe allergic reaction symptoms, such as swelling or trouble breathing, call 911 or your local emergency number right away. These symptoms require immediate medical care because they can become life threatening. If you've had a serious allergic reaction to Zilbrysq, your doctor may recommend taking a different medication warnings for ZilbrysqZilbrysq has a boxed warning. A boxed warning is the most serious warning from the Food and Drug Administration (FDA).Serious meningococcal infectionZilbrysq may increase the risk of serious meningococcal Infection, which can be life threatening. Meningococcal infections include meningitis and you can doBecause of this risk, Zilbrysq is only available through the Risk Evaluation and Mitigation Strategy (REMS) program. Healthcare professionals who prescribe Zilbrysq must be enrolled in the Zilbrysq REMS program. At least 2 weeks before beginning Zilbrysq treatment, your doctor will have you complete or update your meningococcal vaccination to help prevent meningococcal infections as part of the REMS program. Your healthcare professional will continue to monitor you for signs and symptoms of meningococcal infection, even after you've received your you have questions about this, talk with your doctor or side effectsWhile taking Zilbrysq, you may be able to take steps to make side effects easier to manage. If you have problems with side effects that do not go away or worsen, talk with your doctor or pharmacist. They can discuss options for managing side effects or other available treatment was a common side effect reported by people receiving Zilbrysq in studies. Steps you can take to manage symptoms associated with this side effect include:maintaining adequate hydrationtaking over-the-counter antidiarrheal medicationseating bland foods, such as the BRAT dietavoiding spicy or greasy foods that may irritate your stomachNausea and vomitingNausea and vomiting were side effects reported in studies of Zilbrysq. Steps you can take to manage symptoms associated with this side effect include:maintaining adequate hydration eating smaller meals more frequently throughout the daytaking an over-the-counter anti-nausea medicationavoiding foods that are spicy or greasy, which can further irritate the digestive systemPrecautions for ZilbrysqTake note of the following important information to consider before taking has a boxed warning. A boxed warning is the most serious warning from the Food and Drug Administration (FDA). For details, see the 'Boxed warnings for Zilbrysq' precautionsBefore taking Zilbrysq, discuss your health history with your doctor. Zilbrysq may not be right for you if you have certain medical conditions or other factors affecting your health. Be sure to talk with your doctor if any of the following apply to you:pancreatitis certain other infectionsprevious allergic reaction to this or a similar drugpregnancybreastfeedingDisclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
